Respiratory syncytial virus (RSV) in Saudi Arabian children: Epidemiological burden, seasonality, and the evolving landscape of prevention.
文献摘要
Respiratory syncytial virus (RSV) is a major cause of pediatric respiratory disease in Saudi Arabia, particularly among infants during the first six months of life. Saudi studies report RSV detection in approximately 20-26% of hospitalized children with respiratory illness, although estimates vary by population, setting, diagnostic method, and study period. RSV contributes substantially to hospitalization, intensive care admission, mechanical ventilation, and healthcare costs. Circulation is generally seasonal, from autumn to early spring, peaking in December and January, with regional variation and post-COVID-19 shifts. Both RSV-A and RSV-B circulate, highlighting the need for ongoing molecular surveillance. Prevention has historically relied on palivizumab for selected high-risk infants. Emerging strategies, including nirsevimab and maternal prefusion F vaccination, show substantial international effectiveness, although Saudi-specific effectiveness data remain unavailable. Broader infant prevention, strengthened surveillance, locally defined seasonal timing, real-world effectiveness studies, molecular monitoring, and comprehensive economic evaluation are therefore strongly warranted across Saudi Arabia.